Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1989 Jan;209(1):73–80. doi: 10.1097/00000658-198901000-00011

A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques.

K I Bland 1, A K Kimura 1, D E Brenner 1, M A Basinger 1, M Hirsch 1, I F Hawkins Jr 1, K K Pierson 1, E M Copeland 3rd 1
PMCID: PMC1493892  PMID: 2910216

Abstract

A phase II trial was conducted with 15 patients (mean age of 65.7 years) with locally recurrent or intransit melanoma of the extremities. After total outflow occlusion with pneumatic tourniquet, the cell-cycle nonspecific anti-neoplastic agent cis-diamminedicholoroplatinum (CDDP) was infused intra-arterially in a mean dose of 26.7 mg/m2 per infusion (2.6 infusions per patient). The aim of this study was to determine the efficacy of CDDP infusion for control of intransit and recurrent melanoma of the extremities. Three to four weeks postinfusion, all visible residual disease was resected. Partial remissions were observed in ten patients (67%); five patients achieved stable disease status. No patient had complete regression of disease. At an average follow-up interval of 18.3 months (range 4-44 months), the mean local/regional disease-free survival was 14.8 months. Eighty per cent of patients (twelve of 15) had local/regional control of disease at an average follow-up of 14.8 months after CDDP infusion and surgical resection. Of five melanoma-related deaths, three patients had had no local/regional recurrence at the time of their demise. Three compartment syndromes resulted as a complication of the infusional therapy and occurred within 1-3 days of the treatment. In vitro growth of melanoma from lymph nodes draining the infused area was seen in all subjects studied. Outgrowth from tumor within the tourniquet infusion area was observed in two patients, both of whom experienced recurrences clinically at 24-months' postinfusion. Pharmacokinetic data of total CDDP concentrations from tissue and blood (n = 4) were available from pretreatment to 1 hour post-therapy. Biopsy data from patients pre- and post-treatment suggest substantial tumor uptake of CDDP as compared to local or distal normal skin, with minimal CDDP loss to the systemic circulation. Pharmacologic and clinical data of this phase II trial suggest that intraarterial infusion with tourniquet outflow-occlusion augments tumor tissue levels of CDDP within the infused extremity and enhances local control of high-risk and intransit disease.

Full text

PDF
73

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CREECH O., Jr, KREMENTZ E. T., RYAN R. F., WINBLAD J. N. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958 Oct;148(4):616–632. doi: 10.1097/00000658-195810000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Calvo D. B., 3rd, Patt Y. Z., Wallace S., Chuang V. P., Benjamin R. S., Pritchard J. D., Hersh E. M., Bodey G. P., Sr, Mavligit G. M. Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy. Cancer. 1980 Mar 15;45(6):1278–1283. doi: 10.1002/1097-0142(19800315)45:6<1278::aid-cncr2820450603>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  3. Campbell T. N., Howell S. B., Pfeifle C. E., Wung W. E., Bookstein J. Clinical pharmacokinetics of intraarterial cisplatin in humans. J Clin Oncol. 1983 Dec;1(12):755–762. doi: 10.1200/JCO.1983.1.12.755. [DOI] [PubMed] [Google Scholar]
  4. Cavaliere R., Ciocatto E. C., Giovanella B. C., Heidelberger C., Johnson R. O., Margottini M., Mondovi B., Moricca G., Rossi-Fanelli A. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer. 1967 Sep;20(9):1351–1381. doi: 10.1002/1097-0142(196709)20:9<1351::aid-cncr2820200902>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  5. Charnsangavej C., Chuang V. P., Wallace S., Soo C. S., Bowers T. Angiographic appearance of recurrent malignant melanoma before and after intra-arterial chemotherapy. Radiology. 1982 Feb;142(2):347–349. doi: 10.1148/radiology.142.2.7198811. [DOI] [PubMed] [Google Scholar]
  6. Collins J. M. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984 May;2(5):498–504. doi: 10.1200/JCO.1984.2.5.498. [DOI] [PubMed] [Google Scholar]
  7. Einhorn L. H., McBride C. M., Luce J. K., Caoili E., Gottlieb J. A. Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma. Cancer. 1973 Oct;32(4):749–755. doi: 10.1002/1097-0142(197310)32:4<749::aid-cncr2820320403>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  8. Friedman M. A., Kaufman D. A., Williams J. E., Resser K. J., Rosenbaum E. H., Cohen R. J., Glassberg A. B., Blume M. R., Gershow J., Chan E. Y. Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study. Cancer Treat Rep. 1979 Mar;63(3):493–495. [PubMed] [Google Scholar]
  9. Frost D. B., Patt Y. Z., Mavligit G., Chuang V. P., Wallace S. Arterial infusion of dacarbazine and cisplatin for recurrent regionally confined melanoma. Arch Surg. 1985 Apr;120(4):478–480. doi: 10.1001/archsurg.1985.01390280068015. [DOI] [PubMed] [Google Scholar]
  10. Ghussen F., Nagel K., Groth W., Müller J. M., Stützer H. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg. 1984 Dec;200(6):764–768. doi: 10.1097/00000658-198412000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jönsson P. E., Ingvar C., Stridbeck H. Tourniquet infusion with DTIC in therapy-resistant melanoma on the extremities: a pilot study. Recent Results Cancer Res. 1983;86:213–217. doi: 10.1007/978-3-642-82025-0_36. [DOI] [PubMed] [Google Scholar]
  12. Karakousis C. P., Kanter P. M., Lopez R., Moore R., Holyoke E. D. Modes of regional chemotherapy. J Surg Res. 1979 Feb;26(2):134–141. doi: 10.1016/0022-4804(79)90090-8. [DOI] [PubMed] [Google Scholar]
  13. Karakousis C. P., Kanter P. M., Park H. C., Sharma S. D., Moore R., Ewing J. H. Tourniquet infusion versus hyperthermic perfusion. Cancer. 1982 Mar 1;49(5):850–858. doi: 10.1002/1097-0142(19820301)49:5<850::aid-cncr2820490505>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  14. Klein E. S., Ben-Ari G. Y. Isolation perfusion with cisplatin for malignant melanoma of the limbs. Cancer. 1987 Mar 15;59(6):1068–1071. doi: 10.1002/1097-0142(19870315)59:6<1068::aid-cncr2820590604>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  15. Oberfield R. A., Sullivan R. D. Prolonged and continuous regional arterial infusion chemotherapy in patients with melanoma. JAMA. 1969 Jul 7;209(1):75–79. [PubMed] [Google Scholar]
  16. Parratto N. P., Kimura A. K. Isolation and visualization of Met-72-positive, metastatic variants present in B16 melanoma tumor masses. J Cell Biochem. 1988 Mar;36(3):311–322. doi: 10.1002/jcb.240360311. [DOI] [PubMed] [Google Scholar]
  17. Savlov E. D., Hall T. C., Oberfield R. A. Intra-arterial therapy of melanoma with dimethyl triazeno imidazole carboxamide (NSC-45388). Cancer. 1971 Nov;28(5):1161–1164. doi: 10.1002/1097-0142(1971)28:5<1161::aid-cncr2820280512>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  18. Savlov E. D., Hall T. C. Response of localized melanoma to intra-arterial dimethyl triazeno imidazole carboxamide: a case report. J Surg Oncol. 1970;2(4):341–347. doi: 10.1002/jso.2930020405. [DOI] [PubMed] [Google Scholar]
  19. Stehlin J. S., Jr Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet. 1969 Aug;129(2):305–308. [PubMed] [Google Scholar]
  20. Stewart D. J., Benjamin R. S., Zimmerman S., Caprioli R. M., Wallace S., Chuang V., Calvo D., 3rd, Samuels M., Bonura J., Loo T. L. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res. 1983 Feb;43(2):917–920. [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES